Showing results (371-380 of 855) with videos related to
Sort By:
Pageof 86
Current Hematologic Malignancy Reports|February 7, 2014
Maintaining low BCR-ABL signaling output to restrict CML progression and enable persistenceAndreas BurchertCurrent Hematologic Malignancy Reports|October 6, 2016
Sézary Syndrome: Clinical and Biological AspectsRebecca Kohnken, Stephanie Fabbro, Justin Hastings, et al.Current Hematologic Malignancy Reports|April 14, 2017
The Role of Early Molecular Response in the Management of Chronic Phase CMLPatrick Harrington, Aytug Kizilors, Hugues de LavalladeCurrent Hematologic Malignancy Reports|January 25, 2017
The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic LeukemiaBenjamin L Lampson, Matthew S DavidsCurrent Hematologic Malignancy Reports|January 7, 2014
Thinking out of the box--new approaches to controlling GVHDFrédéric Baron, Stéphanie Humblet-Baron, Grégory Ehx, et al.Current Hematologic Malignancy Reports|May 20, 2014
Chemotherapy only in early stage Hodgkin lymphoma: more relapses but the same survival--what to do?Joseph M ConnorsCurrent Hematologic Malignancy Reports|June 1, 2014
Which Hodgkin's patients in the Unites States should be treated with BEACOPP?Bruce D ChesonCurrent Hematologic Malignancy Reports|June 19, 2014
Chemotherapy only in early-stage Hodgkin lymphoma: more relapses but "same" (or possibly worse) survival--reconsidering the misguided trend to omit radiotherapyJoachim YahalomCurrent Hematologic Malignancy Reports|June 20, 2014
Relapsed Hodgkin lymphoma: management strategiesFrancesca Montanari, Catherine DiefenbachCurrent Hematologic Malignancy Reports|August 17, 2012
Biological therapy doublets: pairing rituximab with interferon, lenalidomide, and other biological agents in patients with follicular lymphomaEva KimbyPageof 86